A Phase 1, Open-Label, Non-Randomized, 2-Period, Fixed Sequence Study to Investigate the Absorption, Distribution, Metabolism and Excretion of [14c-Pf-06700841] and to Assess the Absolute Bioavailability and Fraction Absorbed of Pf-06700841 in Healthy Male Subjects using a 14C-Microtracer Approach - PF-06700841 ADME microtracer study

Pfizer, Inc.0 个研究点目标入组 6 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•1.Healthy male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including BP and pulse rate (PR) measurement, 12-lead electrocardiogram (ECG), or clinical laboratory tests.;2.Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).;3.Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.;4.Subjects who are willing and able to comply with study confinement period, scheduled visits, treatment plan, laboratory tests, contraceptive requirements and other study procedures.

•1.Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies).;2.Any clinically significant malabsorption condition (eg, gastrectomy, bowel resection).;3.Inability to have at least one bowel movement every 2 days on average.;4.A positive urine drug screen for drugs of abuse or recreational drugs.

发起方